Researchers Linked IDUA Gene Mutations to Inherited Blindness
The study identifies a potential new genetic cause for retinitis pigmentosa, expanding the role of the IDUA gene.
Updated on Oct. 6, 2026 in Life Sciences
Live Poll
Should doctors perform broader genetic testing for patients experiencing unexplained vision loss?
Researchers have identified that mutations in the IDUA gene can lead to retinitis pigmentosa, a condition causing progressive vision loss. This research suggests the gene should be considered in clinical evaluations of inherited retinal diseases, even in the absence of other systemic symptoms.
Why it matters
The findings broaden the understanding of IDUA mutations, which were previously tied primarily to mucopolysaccharidosis type I, a severe metabolic disorder. Identifying this link helps refine diagnostic testing for patients with isolated blindness.
The study utilized a functional platform to measure residual enzyme activity levels in 14 participants. Genetic testing confirmed that all subjects possessed mutations in both copies of the IDUA gene, resulting in a phenotype limited to ocular health.
The players
Greenwood Genetic Center
A research and clinical facility specializing in the development of diagnostic testing and genetic research.
University of Manchester
A research-intensive university with extensive work in genomics and ocular biology.
The details
The research establishes that specific IDUA gene changes can result in a distinct presentation of retinitis pigmentosa—a group of genetic disorders involving the breakdown and loss of cells in the retina, the light-sensitive tissue at the back of the eye. While the IDUA gene is typically linked to mucopolysaccharidosis type I, a disease characterized by severe heart, skeletal, and physical abnormalities, the participants in this study lacked these metabolic complications. Researchers suggest that some genetic variations allow a residual amount of enzymatic activity to remain in the body, which may be sufficient to avoid systemic disease while still impacting ocular function.
Timeline
October 6, 2026: The study was published in The American Journal of Human Genetics.
The Tech Race
This finding updates the phenotypic range associated with the IDUA gene, which has long been the focus of metabolic diagnostic protocols. It aligns with broader trends in genetic medicine to re-evaluate the full impact of known genes using functional platforms across diverse patient cohorts.
Clinicians may now integrate IDUA gene testing into the diagnostic workflow for patients presenting with inherited retinal disease who lack other metabolic symptoms. This expanded testing protocol aims to improve diagnosis accuracy for patients with previously unexplained vision loss.
The takeaway
The study signals that IDUA gene mutations are a broader clinical factor for blindness than previously recognized in metabolic research. Practitioners should track future guidelines on genetic panel recommendations for patients with unexplained retinal degeneration.
Further reading
For more on evolving diagnostic standards, visit our Life Sciences section.
More information
Review the technical details in the peer reviewed study in AJHG00349-6).
Live Poll
Should doctors perform broader genetic testing for patients experiencing unexplained vision loss?
